Anika Therapeutics (ANIK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Sales | 32,610 | 29,612 | 30,615 | 27,817 | 28,219 |
| Cost of Goods | 11,366 | 10,615 | 11,436 | 12,233 | 13,856 |
| Gross Profit | 21,244 | 18,997 | 19,179 | 15,584 | 14,363 |
| Operating Expenses | 18,656 | 25,100 | 18,969 | 19,050 | 19,399 |
| Operating Income | 2,954 | -5,488 | 646 | -3,233 | -4,180 |
| Other Income | 426 | 667 | 118 | 997 | 214 |
| Pre-tax Income | 3,380 | -4,821 | 764 | -2,236 | -3,966 |
| Income Tax | 71 | 235 | -1,037 | 939 | 681 |
| Net Income Continuous | 3,309 | -5,056 | 1,801 | -3,175 | -4,647 |
| Net Income Discontinuous | N/A | N/A | -1,509 | 846 | 677 |
| Net Income | $3,309 | $-5,056 | $292 | $-2,329 | $-3,970 |
| EPS Basic Total Ops | 0.25 | -0.37 | 0.02 | -0.16 | -0.28 |
| EPS Basic Continuous Ops | 0.25 | -0.37 | 0.13 | -0.22 | -0.33 |
| EPS Basic Discontinuous Ops | N/A | N/A | -0.11 | 0.06 | 0.05 |
| EPS Diluted Total Ops | 0.24 | -0.37 | 0.02 | -0.16 | -0.28 |
| EPS Diluted Continuous Ops | 0.24 | -0.37 | 0.13 | -0.22 | -0.33 |
| EPS Diluted Discontinuous Ops | N/A | N/A | -0.11 | 0.06 | 0.05 |
| EPS Diluted Before Non-Recurring Items | 0.30 | -0.24 | 0.13 | -0.17 | -0.33 |
| EBITDA(a) | $4,459 | $-4,081 | $1,964 | $-1,830 | $-2,764 |